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Abstract The prevalence of type 2 diabetes (T2D) in Asia is
growing at an alarming rate, posing significant clinical and
economic risk to health care stakeholders. Commonly, Asian
patients with T2D manifest a distinctive combination of char-
acteristics that include earlier disease onset, distinct patho-
physiology, syndrome of complications, and shorter life
expectancy. Optimizing treatment outcomes for such patients
requires a coordinated inclusive care plan and knowledgeable
practitioners.Comprehensivemanagementstartswithmedical
nutrition therapy (MNT) in a broader lifestyle modification
program.Implementingdiabetes-specificMNTinAsiarequires
high-quality and transparent clinical practice guidelines (CPGs)
that are regionally adapted for cultural, ethnic, and socioeco-
nomic factors. Respected CPGs for nutrition and diabetes ther-
apy are available from prestigious medical societies. For cost
efficiency and effectiveness, health care authorities can select
these CPGs for Asian implementation following abridgement
and cultural adaptation that includes: defining nutrition therapy
in meaningful ways, selecting lower cutoff values for healthy
body mass indices and waist circumferences (WCs), identify-
ing the dietary composition of MNT based on regional avail-
ability and preference, and expanding nutrition therapy for
concomitant hypertension, dyslipidemia, overweight/obesity,
and chronic kidney disease. An international task force of
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DOI 10.1007/s11892-012-0252-0respected health care professionals has contributed to this pro-
cess. To date, task force members have selected appropriate
evidence-basedCPGsandsimplifiedthemintoanalgorithmfor
diabetes-specific nutrition therapy. Following cultural adapta-
tion, Asian and Asian-Indian versions of this algorithmic tool
have emerged. The Asian version is presented in this report.
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Introduction
Increased urbanization with attendant lifestyle changes and
older populations have led to a marked increase in the
incidence and prevalence of type 2 diabetes (T2D) in many
Asian countries [1–3]. An estimated 60% of the global
population of people with T2D now resides in Asia [4￿],
with the largest numbers of afflicted individuals in India and
China [3]. Epidemiologic shifts in prevalence rates in Asian
countries, which cover Asia continents and several pacific
islands, have imposed an enormous burden on their socie-
ties, resulting in increased morbidity and mortality among
patients who also incur higher health care expenditures.
Unique features of T2D in Asian populations create a
complex and challenging management problem. Asian pop-
ulations are heterogeneous, with different rates of T2D
depending on cultural, ethnic, and socioeconomic variances.
Asians tend to develop T2D at a younger age, have a lesser
degree of diabetes-related obesity, suffer longer from com-
plications, and die earlier compared with other ethnicities
[5]. Asians with T2D experience postprandial hyperglyce-
mia more frequently [6￿]. Moreover, data consistently dem-
onstrate that Asians with T2D have a higher risk of renal
complications compared with patients of European descent
[7]. In a large-scale multinational survey, up to 60% of
Asian patients with T2D had albuminuria versus 30–40%
in a comparative Western cohort [8, 9]. These unique char-
acteristics of T2D in Asians must be considered when
selecting therapeutic options and formulating comprehen-
sive management strategies.
To inform management decisions, most affluent countries
rely on sophisticated health services and prestigious medical
organizationsthatseektoaddressimportantissuesin diabetes.
Likewise, they have developed tools that assist in standardiz-
ingcarefordiabetesandahostofotherdiseasesanddisorders.
For example, sophisticated clinical practice guidelines (CPG)
now exist for most common medical problems, their diagno-
sis, and treatment. Such guidelines help physicians make
challenging decisions, improving outcomes while controlling
costs [10, 11]. In general, CPGs are useful but also have
limitations [2, 11, 12]. Commonly, their recommendations
are based on evidence from clinical studies conducted among
patients with similar demographics, especially those from the
larger more homogeneous segments of their societies. Rarely
arerecommendationsresponsivetoemergentculturalorsocial
factors, which are usually omitted from CPGs, thus severely
limiting their portability [13].
Application of evidence-based recommendations from
Western CPGs to Asian patients with T2D represents a
quintessential example of this portability shortcoming. Life-
styles, foods, and traditions can vary greatly between West-
ern and Asian peoples. Moreover, the availability of medical
resources may be limited compared with Western countries,
and routine clinical practices may be divergent. To improve
the applicability and transportability of guidelines for life-
style modification in diabetes, a transcultural task force was
assembled, a series of international and regional meetings
was convened, and cultural factors that influence the devel-
opment and progression of T2D, as well as its management,
were identified. Thereafter, these factors were incorporated
into a master algorithm for diabetes-nutrition therapy that
can hopefully be applied globally to help control the world-
wide epidemic in cardiometabolic disease.
This paper describes specific task force activities and
findings within Asian countries and contributes to our un-
derstanding of the human characteristics that influence diets,
eating patterns, and lifestyle choices. It also conveys trans-
cultural factors that influence the adaptability of current
evidence-based CPGs for diabetes-specific nutrition therapy
and the implementation of those guidelines within Asian
countries.
Transcultural Factors for Asia
Assessment of Body Composition and Risk of Disease
Progression
Anthropometricmeasures—includingbodymass index(BMI),
WC, and waist-to-hip ratio—are used to assess body compo-
sition and the risk of T2D progression across populations.
However, determinations may be different for Asians com-
pared with white individuals. For example, optimum cutoff
points for obesity vary based on genetic differences between
Asians and whites and the heterogeneous nature of various
Asian populations. The upper BMI values of 25 kg/m
2 for
overweight and 30 kg/m
2 for obese from the World Health
Organization (WHO) are too high for Asians according to
international consensus [14]. In 2000, the WHO Western Pa-
cific Regional Office proposed a modified upper BMI cutoff
value of 23 kg/m
2 for overweight and 25 kg/m
2 for obese in
Asian populations [15]. Likewise, the proposed Asian-specific
WC cutoff values for central adiposity (90 cm for men, 80 cm
for women), which differ from cutoff values for whites (40
inches for men and 35 inches for women) [15], were adopted
214 Curr Diab Rep (2012) 12:213–219bymostAsiancountries[16].InJapan,upperWCcutoffvalues
of 85 cm for men and 90 cm for women were recommended
based on correlation with 100 cm
2 of visceral fat area obtained
by computed tomography scan [17]. Within Asian versions of
the transcultural algorithm for diabetes-nutrition therapy, these
values replace corresponding standards for white patients.
Benefits of Active Lifestyle in Diabetes Management
Recommendations for the comprehensive management of
diabetes encourage patients to maintain an active lifestyle
because physical activity and exercise provide many health
benefits and facilitate glycemic control [18–21]. A Chinese
Da Qing lifestyle study of patients with impaired glucose
tolerance demonstrated that lifestyle interventions can pre-
vent the development of T2D and cardiovascular disease
(CVD) [22]. In response to these observations, most Asian
medical professionals recommend 150 min per week of
moderate-intensity exercise for patients with diabetes as part
of their comprehensive management [18–21]. This recom-
mendation corresponds to similar guidance for white
patients and, therefore, appears unchanged in Asians ver-
sions of the diabetes-specific nutrition algorithm.
Appropriate Selection of Diet for Glycemic Control
Dietary habits and food compositions influence glycemic
control, the development and progression of diabetes, and
the risk of diabetic complications [23]. Unlike the gradual
nutrition transition with large portion and high-energy den-
sity [24] that occurred in the United States and most Euro-
pean countries, the nutrition transition in many Asian
countries has been rapid [25]. In general, the mean per
capita consumption of calories, carbohydrates, protein, and
fats is rising as the economies grow plus industrialization
with sedentary life pattern [26, 27]. Appropriate dietary
education based on individual risk factors such as prediabetes
or T2D, cardiometabolic status, medicinal use, and degree of
overweight/obesity is needed to facilitate the implementation
and acceptance of dietary recommendations. Information
about foods with higher glycemic indices (GI) or glycemic
loads (GL) should be emphasized, since Asians with T2D are
more prone to postprandial hyperglycemia [6￿]. For instance,
“glutinous” short grain rice is a relatively highglycemicindex
food [28], and is a popular carbohydrate staple. Replacing or
exchangingquantitiesofthisgrainwithlowerGIorGLgrains
would have salutary effects on overall glycemic control [29].
Medical Nutrition Therapy and Weight Loss in Diabetes
Management
Medical nutrition therapy (MNT) is an important component
of any comprehensive management program for prediabetes
and diabetes in both Asian and white patients alike. It consists
of nutritional assessment and counseling, as well as specific
dietary modifications intended to improve glycemic and
weight control [30]. Evidence-based research strongly sug-
gests that MNT provided by a registered dietitian who is
experienced in the management of diabetes is clinically effec-
tive. Incorporating MNT into diabetes-specific nutritional
management has been shown to improve glycemic profiles
and reduce the risk of disease complications [31]. MNT also
can lead to moderate weight reduction that ameliorates insulin
resistance, endothelial dysfunction, and dyslipidemias
[32–34]. Randomized controlled studies have shown about
1% reductions in hemoglobin A1c (HbA1c) in new patients
withtype1 diabetes, 2%reductionsinnew patients withT2D,
and 1% in patients with T2D of 4 years average duration [30].
IntheinitialtreatmentofT2D,MNTshouldbecombinedwith
physical activity in a lifestyle modification plan for individu-
als with fasting plasma glucose levels of less than 200 mg/dL.
Patients withT2D who cannot achieve acceptable treatment
goals or who experience disease progression due to β-cell
failure should intensify lifestyle modification and start pre-
scription medication.
Although several MNT guidelines have arisen from
Asian countries (Table 1), the effects of MNT on glycemic
control in Asians with T2D are still unclear and require
further investigation. However, at least one randomized
controlled trial has reported the effectiveness of dietitian-
led diabetes management on diet and glycemic control in a
primary care setting in Taiwan [37]. In that study, patients
with HbA1c measurements of 7% or higher had significantly
greater improvements in fasting plasma glucose and HbA1c
levels at 1 year than control subjects or interventional sub-
jects with HbA1c levels of less than 7%. The study conclud-
ed that diabetes nutrition therapy led by a registered dietitian
can help to improve glycemic control in patients with poorly
managed T2D in a primary care clinic. These results, cou-
pled with similar findings in related international research
reported elsewhere in this journal, have generated a general
interest in MNT for Asians and the willingness of Asian task
forcememberstosupportthenutritionalgorithmwithregional
adaptations for MNT.
Use of Diabetes-Specific Formulas to Facilitate Glycemic
Control
Diabetes-specific (glycemia targeted specialized) nutrition
formulas are nutrition-rich calorie replacements for normal,
overweight, or obese individuals or calorie supplements for
underweight individuals with T2D. They are associated with
demonstrable benefits in glycemic control parameters. Typ-
ically, MNT programs include diabetes-specific formula
(DSF) in their armamentariums. In a study involving
insulin-treated patients with T2D who received enteral
Curr Diab Rep (2012) 12:213–219 215nutrition, the use of a low-carbohydrate, high monounsatu-
rated fatty acid formula improved glycemic control com-
pared with a standard enteral nutrition formula [38]. A more
recent study showed that postprandial glucose responses
were lower and were maintained during a 4-week trial of
DSF in patients with T2D [39￿]. Additionally, a systematic
review showed that short-term and long-term use of DSF as
oral supplementation and enteral nutrition support are asso-
ciated with improved glycemic control compared with stan-
dard formulas [40].
Further research is required to determine if studies con-
ducted in Western populations can be extrapolated to other
cultural settings. For example, some Asian subpopulations
have lactose intolerance, which might hinder the use of
milk-based DSF products [41]. Potential remedies for this
problem include exogenous β-galactosidase, yogurt, and
other probiotics that can be ingested for their bacterial
lactase activity, and pharmacologic or nonpharmacologic
interventions that can help to overcome intestinal malab-
sorption [42]. Again, further investigation is required.
Bariatric Surgery for Patients with T2D and Obesity
The International Diabetes Federation (IDF) Taskforce on
Epidemiology and Prevention of Diabetes recently an-
nounced that certain bariatric surgical procedures can sig-
nificantly improve glycemic control in severely obese
patients with T2D [43]. The IDF recommends the devel-
opment of national guidelines for bariatric surgery for
people with T2D with a BMI ≥35 kg/m
2. For Asians
and other ethnicities with increased cardiometabolic risks,
intervention may be appropriate at lower BMI (eg, 27.5–
32.5 kg/m
2). Given the increase in the number of at-risk
Asians, there is an imperative to scientifically establish
BMI action points and to develop effective plans for their
implementation [44].
Nutritional Management of Patients with Comorbid
Conditions: Hypertension, Dyslipidemia, and/or Chronic
Kidney Disease
The prevalence and awareness of hypertension varies
around the world [45]. In Asian countries, an increased
incidence of hypertension has been observed [46]. Conse-
quently, the prevalence of hypertension in men is expected
to increase to 65.4% compared with 51.2% in the rest of the
world. Likewise, the prevalence of hypertension is expected
to increase rapidly in Asian women following an 81.6%
increase in incidence rates compared with a 54.4% increase
in incidence in the rest of the world.
Hypertension, with or without nephropathy, is more dif-
ficult to control in the presence of T2D. The majority of
patients with T2D require two or more drugs to reach
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216 Curr Diab Rep (2012) 12:213–219desired blood pressure targets. As part of overall manage-
ment, lifestyle modification can be implemented according
to the S-ABCDE mnemonic: salt restriction, alcohol limita-
tion, body weight reduction, cessation of smoking, diet
adaptation, and exercise adoption [47]. The generally ac-
cepted recommended daily intake for sodium is a maximum
of 2.4 g of sodium or 6 g of sodium chloride. The Dietary
Approaches to Stop Hypertension (DASH) diet emphasizes
fruits, vegetables, and low-fat dairy products and includes
whole grains, poultry, fish, and nuts, as well as reduced fats,
red meat, sweets, and sugary drinks [48]. The DASH diet
can reduce systolic and diastolic blood pressure by 11.4 and
5.5 mm Hg, respectively, in hypertensive patients [49].
However, because of its relatively high potassium, phospho-
rus, and protein content, the DASH diet is not recommended
for patients with stage 3 or 4 chronic kidney disease (CKD)
with an estimated glomerular filtration rate of less than
60 mL/min/1.73 m
2 [50].
Randomized clinical trials have confirmed the benefits of
using statins to reduce low-density lipoprotein cholesterol in
preventing CVD. There is strong evidence delineating the
pathophysiologic roles of T2D and dyslipidemia in cardi-
orenal disease and the benefits of lipid-lowering treatments
[51]. It is believed that the high rate of CKD with T2D, a
close link to CVD, and the benefits of lipid-lowering treat-
ments on renal function are all relevant for cardiometabolic
risk reduction and disease management. For patients with
CKD and T2D, a limited protein intake is recommended:
0.8–1 . 0g / k gi ns t a g e s1 –2 and less than 0.8 g/kg in
stage 3 or greater [52]. Although most national guide-
lines use criteria similar to the Western world for man-
agement of dyslipidemia in patients with T2D, there are
consistently low rates of lipid-lowering drug use and
attainment of treatment goals in Asia [53]. This imple-
mentation hindrance resonates with the need for the
transculturalization of established CPGs.
Conclusions
MNT is an essential component in the comprehensive man-
agement of prediabetes and T2D. In appropriately selected
patients, it precedes the initiation of pharmacologic therapy
and is prescribed concomitantly thereafter. Numerous CPGs
for diabetes-specific nutrition are available from prestigious
medical societies and health care services but have limited
portability to Asian countries. However, with rigorous cul-
tural adaptations they can be modified, implemented, and
adopted regionally throughout Asia. To achieve these objec-
tives, an international task force developed a transcultural
diabetes-specific nutrition algorithm that simplifies complex
diabetes guidelines into aneasy-to-use format that is adaptable.
The Asian adaptation accommodates regional differences in
lifestyles, foods, and customs to meet the needs and preferen-
ces of afflicted patients. Future efforts for this region will focus
ondefiningadditionalquestionsregardingtransculturalfactors,
developing and implementing facile tools that can improve
clinical outcomes in a cost-effective manner, and perhaps
modulatingthehealthpromotionculturesothatcomprehensive
primary prevention strategies can be more successful.
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